Signature Estate & Investment Advisors LLC Grows Stock Position in Boston Scientific Corporation $BSX

Signature Estate & Investment Advisors LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 14.4% in the fourth quarter, Holdings Channel reports. The fund owned 79,989 shares of the medical equipment provider’s stock after buying an additional 10,071 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Boston Scientific were worth $7,627,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Claret Asset Management Corp boosted its holdings in Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC boosted its holdings in Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after acquiring an additional 103 shares during the period. Outfitters Financial LLC boosted its holdings in Boston Scientific by 0.5% in the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after acquiring an additional 110 shares during the period. Fayez Sarofim & Co boosted its position in Boston Scientific by 2.1% in the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock valued at $520,000 after buying an additional 111 shares during the last quarter. Finally, Natural Investments LLC boosted its position in Boston Scientific by 2.9% in the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after buying an additional 112 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Insider purchases are often viewed as a sign of management confidence in the company’s outlook and can support sentiment around the stock.
• Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter. The FRACTURE trial met all primary safety and effectiveness endpoints, which strengthens the case for a future regulatory submission and supports the company’s growth story in interventional cardiology.
• Neutral Sentiment: Baird kept an Outperform rating on Boston Scientific, though it trimmed its price target to $75 from $78. That suggests the firm still sees upside, but the lower target may temper enthusiasm somewhat.
• Negative Sentiment: Recent commentary also pointed to Boston Scientific having fallen on weak results, and the stock remains well below its longer-term moving averages. That indicates investors are still weighing execution concerns and broader pressure on the shares despite the upbeat insider and clinical developments.

Wall Street Analyst Weigh In

BSX has been the subject of a number of analyst reports. The Goldman Sachs Group decreased their price objective on shares of Boston Scientific from $87.00 to $84.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Wells Fargo & Company decreased their price objective on shares of Boston Scientific from $94.00 to $75.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research report on Monday, February 2nd. Jefferies Financial Group decreased their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Finally, Canaccord Genuity Group reduced their target price on Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $92.71.

Boston Scientific Stock Performance

Shares of BSX opened at $57.08 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The business’s fifty day moving average price is $62.21 and its 200 day moving average price is $80.40. Boston Scientific Corporation has a 12-month low of $52.52 and a 12-month high of $109.50. The stock has a market capitalization of $84.84 billion, a PE ratio of 23.88, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter last year, the company posted $0.75 earnings per share. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific announced that its board has authorized a share buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This represents a 16.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.